Functional oncoimaging techniques with potential clinical applications

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 3, 2012, Pages 1081-1096

  Kwee, Thomas C ^a   Basu, Sandip ^b   Saboury, Babak ^c   Alavi, Abass ^c   Torigian, Drew A ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cancer; CT; Functional imaging; Molecular imaging; MRI; PET; Review

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; ANTIMONY TECHNETIUM SULFIDE TC 99M; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; IODINATED CONTRAST MEDIUM; METHIONINE C 11; NANOCOLL TC 99M; O (2 FLUOROETHYL) TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TECHNETIUM SULFUR COLLOID TC 99M; TRACER; TYROSINE DERIVATIVE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISTANT METASTASIS; DRUG UPTAKE; ELASTOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOMA; GLUCOSE METABOLISM; HUMAN; HYPOXEMIA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAGNETIC RESONANCE ELASTOGRAPHY; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE OXYGENATION; TUMOR VASCULARIZATION; LYMPH NODE; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

HUMANS; LYMPH NODES; MAGNETIC RESONANCE IMAGING; NEOPLASMS;

EID: 84860877605     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (114)

1. A. Jemal, R. Siegel, J. Xu and E. Ward: Cancer statistics, 2010. CA Cancer J Clin, 60(5), 277-300 (2010)
2. D. A. Torigian, S. S. Huang, M. Houseni and A. Alavi: Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin, 57(4), 206-24 (2007) (Pubitemid 47312081)
3. J. Barentsz, S. Takahashi, W. Oyen, R. Mus, P. De Mulder, R. Reznek, M. Oudkerk and W. Mali: Commonly used imaging techniques for diagnosis and staging. J Clin Oncol, 24(20), 3234-44 (2006)
4. M. Schnall and M. Rosen: Primer on imaging technologies for cancer. J Clin Oncol, 24(20), 3225-33 (2006) (Pubitemid 46622063)
5. M. Atri: New technologies and directed agents for applications of cancer imaging. J Clin Oncol, 24(20), 3299-308 (2006) (Pubitemid 46622070)
6. D. W. Townsend: Dual-modality imaging: combining anatomy and function. J Nucl Med, 49(6), 938-55 (2008) (Pubitemid 351793435)
7. J. Folkman: Tumor angiogenesis: therapeutic implications. N Engl J Med, 285(21), 1182-6 (1971)
8. V. Goh and A. R. Padhani: Imaging tumor angiogenesis: functional assessment using MDCT or MRI? Abdom Imaging, 31(2), 194-9 (2006)
9. A. R. Padhani: Dynamic contrast-enhanced MR imaging. Cancer Imaging, 1, 52-63 (2000)
10. N. Hylton: Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol, 24(20), 3293-8 (2006) (Pubitemid 46622069)
11. E. Stejskal and J. Tanner: Spin diffusion measurements: spin echoes in the presence of a timedependent field gradient. . J Chem Phys, 42, 288-292 (1965)
12. P. W. Schaefer, P. E. Grant and R. G. Gonzalez: Diffusion-weighted MR imaging of the brain. Radiology, 217(2), 331-45 (2000)
13. D. M. Koh and D. J. Collins: Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol, 188(6), 1622-35 (2007) (Pubitemid 46866868)
14. A. R. Padhani, G. Liu, D. M. Koh, T. L. Chenevert, H. C. Thoeny, T. Takahara, A. Dzik-Jurasz, B. D. Ross, M. Van Cauteren, D. Collins, D. A. Hammoud, G. J. Rustin, B. Taouli and P. L. Choyke: Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia, 11(2), 102-25 (2009)
15. T. Takahara, Y. Imai, T. Yamashita, S. Yasuda, S. Nasu and M. Van Cauteren: Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med, 22(4), 275-82 (2004) (Pubitemid 39264807)
16. H. Nomori, T. Mori, K. Ikeda, K. Kawanaka, S. Shiraishi, K. Katahira and Y. Yamashita: Diffusionweighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of nonsmall cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg, 135(4), 816-22 (2008) (Pubitemid 351417933)
17. Y. Ohno, H. Koyama, Y. Onishi, D. Takenaka, M. Nogami, T. Yoshikawa, S. Matsumoto, Y. Kotani and K. Sugimura: Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for wholebody diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology, 248(2), 643-54 (2008)
18. D. Takenaka, Y. Ohno, K. Matsumoto, N. Aoyama, Y. Onishi, H. Koyama, M. Nogami, T. Yoshikawa, S. Matsumoto and K. Sugimura: Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), wholebody MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging, 30(2), 298-308 (2009)
19. R. Murakami, T. Hirai, T. Sugahara, H. Fukuoka, R. Toya, S. Nishimura, M. Kitajima, T. Okuda, H. Nakamura, N. Oya, J. Kuratsu and Y. Yamashita: Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one-versus two-parameter pilot method. Radiology, 251(3), 838-45 (2009)
20. T. Mori, H. Nomori, K. Ikeda, K. Kawanaka, S. Shiraishi, K. Katahira and Y. Yamashita: Diffusionweighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol, 3(4), 358-64 (2008) (Pubitemid 351489475)
21. Y. Ohba, H. Nomori, T. Mori, K. Ikeda, H. Shibata, H. Kobayashi, S. Shiraishi and K. Katahira: Is diffusionweighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg, 138(2), 439-45 (2009)
22. M. Nakajo, Y. Kajiya, T. Kaneko, Y. Kaneko, T. Takasaki, A. Tani, M. Ueno and C. Koriyama: FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging, 37(11), 2011-20 (2010)
23. D. A. Hamstra, A. Rehemtulla and B. D. Ross: Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol, 25(26), 4104-9 (2007) (Pubitemid 47495868)
24. D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, B. D. Ross and T. L. Chenevert: Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol, 26(20), 3387-94 (2008)
25. C. J. Galban, S. K. Mukherji, T. L. Chenevert, C. R. Meyer, D. A. Hamstra, P. H. Bland, T. D. Johnson, B. A. Moffat, A. Rehemtulla, A. Eisbruch and B. D. Ross: A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol, 2(3), 184-90 (2009)
26. B. Ma, C. R. Meyer, M. D. Pickles, T. L. Chenevert, P. H. Bland, C. J. Galban, A. Rehemtulla, L. W. Turnbull and B. D. Ross: Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging, 21, 276-87 (2009)
27. K. C. Lee, D. A. Bradley, M. Hussain, C. R. Meyer, T. L. Chenevert, J. A. Jacobson, T. D. Johnson, C. J. Galban, A. Rehemtulla, K. J. Pienta and B. D. Ross: A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia, 9(12), 1003-11 (2007) (Pubitemid 350255347)
28. C. Beaulieu: The basis of anisotropic water diffusion in the nervous system -A technical review. NMR Biomed, 15(7-8), 435-55 (2002) doi:10.1002/nbm.782 (Pubitemid 36054508)
29. P. Hagmann, L. Jonasson, P. Maeder, J. P. Thiran, V. J. Wedeen and R. Meuli: Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics, 26 Suppl 1, S205-23 (2006)
30. C. Nimsky, O. Ganslandt, P. Hastreiter, R. Wang, T. Benner, A. G. Sorensen and R. Fahlbusch: Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery, 56(1), 130-7; discussion 138 (2005) (Pubitemid 40053995)
31. C. Nimsky, O. Ganslandt, P. Hastreiter, R. Wang, T. Benner, A. G. Sorensen and R. Fahlbusch: Intraoperative diffusion-tensor MR imaging: shifting of white matter tracts during neurosurgical procedures-initial experience. Radiology, 234(1), 218-25 (2005) (Pubitemid 39658389)
32. C. Nimsky, O. Ganslandt, P. Hastreiter, R. Wang, T. Benner, A. G. Sorensen and R. Fahlbusch: Preoperative and intraoperative diffusion tensor imaging-based fiber tracking in glioma surgery. Neurosurgery, 61(1 Suppl), 178-85; discussion 186 (2007)
33. Y. K. Mariappan, K. J. Glaser and R. L. Ehman: Magnetic resonance elastography: a review. Clin Anat, 23(5), 497-511 (2010)
34. R. Muthupillai, D. J. Lomas, P. J. Rossman, J. F. Greenleaf, A. Manduca and R. L. Ehman: Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science, 269(5232), 1854-7 (1995)
35. L. Huwart, C. Sempoux, E. Vicaut, N. Salameh, L. Annet, E. Danse, F. Peeters, L. C. ter Beek, J. Rahier, R. Sinkus, Y. Horsmans and B. E. Van Beers: Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology, 135(1), 32-40 (2008) (Pubitemid 351899024)
36. T. A. Krouskop, P. S. Younes, S. Srinivasan, T. Wheeler and J. Ophir: Differences in the compressive stress-strain response of infiltrating ductal carcinomas with and without lobular features-implications for mammography and elastography. Ultrason Imaging, 25(3), 162-70 (2003) (Pubitemid 38159966)
37. R. Sinkus, K. Siegmann, T. Xydeas, M. Tanter, C. Claussen and M. Fink: MR elastography of breast lesions: understanding the solid/liquid duality can improve the specificity of contrast-enhanced MR mammography. Magn Reson Med, 58(6), 1135-44 (2007) (Pubitemid 350234200)
38. M. Torabi, S. L. Aquino and M. G. Harisinghani: Current concepts in lymph node imaging. J Nucl Med, 45(9), 1509-18 (2004) (Pubitemid 47618505)
39. J. F. Thompson and R. F. Uren: Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncol, 6(11), 877-85 (2005) (Pubitemid 41614800)
40. J. R. Benson, I. Jatoi, M. Keisch, F. J. Esteva, A. Makris and V. C. Jordan: Early breast cancer. Lancet, 373(9673), 1463-79 (2009)
41. V. Ficarra and A. Galfano: Should the dynamic sentinel node biopsy (DSNB) be considered the gold standard in the evaluation of lymph node status in patients with penile carcinoma? Eur Urol, 52(1), 17-9; discussion 20-1 (2007) (Pubitemid 46803031)
42. B. J. Czerniecki, I. Bedrosian, M. Faries and A. Alavi: Revolutionary impact of lymphoscintigraphy and intraoperative sentinel node mapping in the clinical practice of oncology. Semin Nucl Med, 31(2), 158-64 (2001) (Pubitemid 32298300)
43. T. K. Lam, R. F. Uren, R. A. Scolyer, M. J. Quinn, K. F. Shannon and J. F. Thompson: False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Res, 19(2), 94-9 (2009)
44. A. Goyal, A. G. Douglas-Jones, R. G. Newcombe and R. E. Mansel: Effect of lymphatic tumor burden on sentinel lymph node biopsy in breast cancer. Breast J, 11(3), 188-94 (2005) (Pubitemid 40664062)
45. J. A. Leijte, I. M. van der Ploeg, R. A. Valdes Olmos, O. E. Nieweg and S. Horenblas: Visualization of tumor blockage and rerouting of lymphatic drainage in penile cancer patients by use of SPECT/CT. J Nucl Med, 50(3), 364-7 (2009)
46. R. Weissleder, G. Elizondo, J. Wittenberg, A. S. Lee, L. Josephson and T. J. Brady: Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology, 175(2), 494-8 (1990) (Pubitemid 20135291)
47. O. Will, S. Purkayastha, C. Chan, T. Athanasiou, A. W. Darzi, W. Gedroyc and P. P. Tekkis: Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol, 7(1), 52-60 (2006) (Pubitemid 43025393)
48. V. Vandecaveye, F. De Keyzer, V. Vander Poorten, P. Dirix, E. Verbeken, S. Nuyts and R. Hermans: Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology, 251(1), 134-46 (2009)
49. J. K. Kim, K. A. Kim, B. W. Park, N. Kim and K. S. Cho: Feasibility of diffusion-weighted imaging in the differentiation of metastatic from nonmetastatic lymph nodes: early experience. J Magn Reson Imaging, 28(3), 714-9 (2008)
50. M. Eiber, A. J. Beer, K. Holzapfel, R. Tauber, C. Ganter, G. Weirich, B. J. Krause, E. J. Rummeny and J. Gaa: Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusionweighted MR-imaging. Invest Radiol, 45(1), 15-23 (2010)
51. G. Nakai, M. Matsuki, Y. Inada, F. Tatsugami, M. Tanikake, I. Narabayashi and T. Yamada: Detection and evaluation of pelvic lymph nodes in patients with gynecologic malignancies using body diffusion-weighted magnetic resonance imaging. J Comput Assist Tomogr, 32(5), 764-8 (2008)
52. G. Lin, K. C. Ho, J. J. Wang, K. K. Ng, Y. Y. Wai, Y. T. Chen, C. J. Chang, S. H. Ng, C. H. Lai and T. C. Yen: Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging, 28(1), 128-35 (2008) (Pubitemid 351956475)
53. A. Alavi, J. W. Kung and H. Zhuang: Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med, 34(1), 56-69 (2004) (Pubitemid 38056404)
54. F. C. Rau, W. A. Weber, H. J. Wester, M. Herz, I. Becker, A. Kruger, M. Schwaiger and R. Senekowitsch-Schmidtke: O-(2-[(18)F]Fluoroethyl)-L-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging, 29(8), 1039-46 (2002)
55. A. H. Jacobs, A. Thomas, L. W. Kracht, H. Li, C. Dittmar, G. Garlip, N. Galldiks, J. C. Klein, J. Sobesky, R. Hilker, S. Vollmar, K. Herholz, K. Wienhard and W. D. Heiss: 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med, 46(12), 1948-58 (2005) (Pubitemid 46657440)
56. D. Pauleit, G. Stoffels, W. Schaden, K. Hamacher, D. Bauer, L. Tellmann, H. Herzog, S. Broer, H. H. Coenen and K. J. Langen: PET with O-(2-18F-Fluoroethyl)-LTyrosine in peripheral tumors: first clinical results. J Nucl Med, 46(3), 411-6 (2005) (Pubitemid 43093148)
57. S. Hoegerle, C. Altehoefer, N. Ghanem, G. Koehler, C. F. Waller, H. Scheruebl, E. Moser and E. Nitzsche: Wholebody 18F dopa PET for detection of gastrointestinal carcinoid tumors. Radiology, 220(2), 373-80 (2001) (Pubitemid 32667172)
58. W. Chen, D. H. Silverman, S. Delaloye, J. Czernin, N. Kamdar, W. Pope, N. Satyamurthy, C. Schiepers and T. Cloughesy: 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med, 47(6), 904-11 (2006) (Pubitemid 46939941)
59. J. S. Rasey, J. R. Grierson, L. W. Wiens, P. D. Kolb and J. L. Schwartz: Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med, 43(9), 1210-7 (2002) (Pubitemid 34988769)
60. A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske and M. Hetzel: Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med, 44(9), 1426-31 (2003)
61. B. S. Pio, C. K. Park, R. Pietras, W. A. Hsueh, N. Satyamurthy, M. D. Pegram, J. Czernin, M. E. Phelps and D. H. Silverman: Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol, 8(1), 36-42 (2006) (Pubitemid 44201576)
62. D. L. Francis, D. Visvikis, D. C. Costa, T. H. Arulampalam, C. Townsend, S. K. Luthra, I. Taylor and P. J. Ell: Potential impact of [18F]3'-deoxy-3'- fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging, 30(7), 988-94 (2003) (Pubitemid 37086941)
63. P. Vaupel, A. Mayer, S. Briest and M. Hockel: Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol, 566, 333-42 (2005) (Pubitemid 43779520)
64. J. P. Kirkpatrick, L. I. Cardenas-Navia and M. W. Dewhirst: Predicting the effect of temporal variations in PO2 on tumor radiosensitivity. Int J Radiat Oncol Biol Phys, 59(3), 822-33 (2004) (Pubitemid 38748748)
65. J. S. Rasey, Z. Grunbaum, S. Magee, N. J. Nelson, P. L. Olive, R. E. Durand and K. A. Krohn: Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res, 111(2), 292-304 (1987) (Pubitemid 17156952)
66. S. M. Evans, S. Hahn, D. R. Pook, W. T. Jenkins, A. A. Chalian, P. Zhang, C. Stevens, R. Weber, G. Weinstein, I. Benjamin, N. Mirza, M. Morgan, S. Rubin, W. G. McKenna, E. M. Lord and C. J. Koch: Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res, 60(7), 2018-24 (2000) (Pubitemid 30207665)
67. S. M. Evans, K. D. Judy, I. Dunphy, W. T. Jenkins, P. T. Nelson, R. Collins, E. P. Wileyto, K. Jenkins, S. M. Hahn, C. W. Stevens, A. R. Judkins, P. Phillips, B. Geoerger and C. J. Koch: Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res, 64(5), 1886-92 (2004) (Pubitemid 38428715)
68. A. R. Padhani: Where are we with imaging oxygenation in human tumours? Cancer Imaging, 5, 128-30 (2005)
69. M. C. Krishna, S. Subramanian, P. Kuppusamy and J. B. Mitchell: Magnetic resonance imaging for in vivo assessment of tissue oxygen concentration. Semin Radiat Oncol, 11(1), 58-69 (2001) (Pubitemid 32056009)
70. G. Meisetschlager, T. Poethko, A. Stahl, I. Wolf, K. Scheidhauer, M. Schottelius, M. Herz, H. J. Wester and M. Schwaiger: Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide. J Nucl Med, 47(4), 566-73 (2006) (Pubitemid 46768456)
71. W. B. Eubank and D. A. Mankoff: Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med, 35(2), 84-99 (2005) (Pubitemid 40568742)
72. F. Dehdashti, F. L. Flanagan, J. E. Mortimer, J. A. Katzenellenbogen, M. J. Welch and B. A. Siegel: Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med, 26(1), 51-6 (1999) (Pubitemid 29137739)
73. H. M. Linden, S. A. Stekhova, J. M. Link, J. R. Gralow, R. B. Livingston, G. K. Ellis, P. H. Petra, L. M. Peterson, E. K. Schubert, L. K. Dunnwald, K. A. Krohn and D. A. Mankoff: Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol, 24(18), 2793-9 (2006) (Pubitemid 46630578)
74. A. J. Beer, R. Haubner, M. Sarbia, M. Goebel, S. Luderschmidt, A. L. Grosu, O. Schnell, M. Niemeyer, H. Kessler, H. J. Wester, W. A. Weber and M. Schwaiger: Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res, 12(13), 3942-9 (2006) (Pubitemid 44078079)
75. A. G. Knudson: Cancer genetics. Am J Med Genet, 111(1), 96-102 (2002) (Pubitemid 34761590)
76. I. Serganova and R. Blasberg: Reporter gene imaging: potential impact on therapy. Nucl Med Biol, 32(7), 763-80 (2005) (Pubitemid 41502983)
77. S. D. Caruthers, P. M. Winter, S. A. Wickline and G. M. Lanza: Targeted magnetic resonance imaging contrast agents. Methods Mol Med, 124, 387-400 (2006)
78. E. A. Schellenberger, D. Hogemann, L. Josephson and R. Weissleder: Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Acad Radiol, 9 Suppl 2, S310-1 (2002) (Pubitemid 34857703)
79. A. M. Aisen and T. L. Chenevert: MR spectroscopy: clinical perspective. Radiology, 173(3), 593-9 (1989) (Pubitemid 20007179)
80. C. Mountford, C. Lean, P. Malycha and P. Russell: Proton spectroscopy provides accurate pathology on biopsy and in vivo. J Magn Reson Imaging, 24(3), 459-77 (2006) (Pubitemid 44320548)
81. U. Sharma, A. Mehta, V. Seenu and N. R. Jagannathan: Biochemical characterization of metastatic lymph nodes of breast cancer patients by in vitro 1H magnetic resonance spectroscopy: a pilot study. Magn Reson Imaging, 22(5), 697-706 (2004) (Pubitemid 38692630)
82. J. Kurhanewicz, D. B. Vigneron and S. J. Nelson: Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia, 2(1-2), 166-89 (2000) (Pubitemid 30123187)
83. W. Hollingworth, L. S. Medina, R. E. Lenkinski, D. K. Shibata, B. Bernal, D. Zurakowski, B. Comstock and J. G. Jarvik: A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol, 27(7), 1404-11 (2006) (Pubitemid 44260118)
84. C. Majos, C. Aguilera, J. Alonso, M. Julia-Sape, S. Castaner, J. J. Sanchez, A. Samitier, A. Leon, A. Rovira and C. Arus: Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol, 30(3), 544-51 (2009)
85. A. Stadlbauer, S. Gruber, C. Nimsky, R. Fahlbusch, T. Hammen, R. Buslei, B. Tomandl, E. Moser and O. Ganslandt: Preoperative grading of gliomas by using metabolite quantification with high-spatial-resolution proton MR spectroscopic imaging. Radiology, 238(3), 958-69 (2006) (Pubitemid 43289928)
86. A. Laprie, I. Catalaa, E. Cassol, T. R. McKnight, D. Berchery, D. Marre, J. M. Bachaud, I. Berry and E. C. Moyal: Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study. Int J Radiat Oncol Biol Phys, 70(3), 773-81 (2008) (Pubitemid 351199728)
87. I. Park, G. Tamai, M. C. Lee, C. F. Chuang, S. M. Chang, M. S. Berger, S. J. Nelson and A. Pirzkall: Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys, 69(2), 381-9 (2007) (Pubitemid 47380095)
88. J. Oh, R. G. Henry, A. Pirzkall, Y. Lu, X. Li, I. Catalaa, S. Chang, W. P. Dillon and S. J. Nelson: Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging, 19(5), 546-54 (2004) (Pubitemid 38619916)
89. P. Weybright, P. C. Sundgren, P. Maly, D. G. Hassan, B. Nan, S. Rohrer and L. Junck: Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol, 185(6), 1471-6 (2005)
90. E. A. Smith, R. C. Carlos, L. R. Junck, C. I. Tsien, A. Elias and P. C. Sundgren: Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol, 192(2), W45-52 (2009)
91. L. Bartella, E. A. Morris, D. D. Dershaw, L. Liberman, S. B. Thakur, C. Moskowitz, J. Guido and W. Huang: Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology, 239(3), 686-92 (2006) (Pubitemid 43830603)
92. S. G. Cho, D. H. Lee, K. Y. Lee, H. Ji, K. H. Lee, P. R. Ros and C. H. Suh: Differentiation of chronic focal pancreatitis from pancreatic carcinoma by in vivo proton magnetic resonance spectroscopy. J Comput Assist Tomogr, 29(2), 163-9 (2005) (Pubitemid 40411298)
93. J. F. Faria, S. M. Goldman, J. Szejnfeld, H. Melo, C. Kater, P. Kenney, M. P. Huayllas, G. Demarchi, V. V. Francisco, C. Andreoni, M. Srougi, V. Ortiz and N. Abdalla: Adrenal masses: characterization with in vivo proton MR spectroscopy-initial experience. Radiology, 245(3), 788-97 (2007) (Pubitemid 350127349)
94. M. M. Mahon, A. D. Williams, W. P. Soutter, I. J. Cox, G. A. McIndoe, G. A. Coutts, R. Dina and N. M. deSouza: 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR Biomed, 17(1), 1-9 (2004) (Pubitemid 38332095)
95. P. Swindle, S. McCredie, P. Russell, U. Himmelreich, M. Khadra, C. Lean and C. Mountford: Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology, 228(1), 144-51 (2003) (Pubitemid 36736082)
96. C. K. Wang, C. W. Li, T. J. Hsieh, S. H. Chien, G. C. Liu and K. B. Tsai: Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology, 232(2), 599-605 (2004)
97. F. Schick: Whole-body MRI at high field: technical limits and clinical potential. Eur Radiol, 15(5), 946-59 (2005) (Pubitemid 41166727)
98. J. T. Vaughan, C. J. Snyder, L. J. DelaBarre, P. J. Bolan, J. Tian, L. Bolinger, G. Adriany, P. Andersen, J. Strupp and K. Ugurbil: Whole-body imaging at 7T: preliminary results. Magn Reson Med, 61(1), 244-8 (2009)
99. I. Tkac, G. Oz, G. Adriany, K. Ugurbil and R. Gruetter: In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T. Magn Reson Med, 62(4), 868-79 (2009)
100. D. W. Klomp, A. K. Bitz, A. Heerschap and T. W. Scheenen: Proton spectroscopic imaging of the human prostate at 7 T. NMR Biomed, 22(5), 495-501 (2009)
101. P. Narayan, P. Jajodia, J. Kurhanewicz, A. Thomas, J. MacDonald, B. Hubesch, M. Hedgcock, C. M. Anderson, T. L. James, E. A. Tanagho and et al.: Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report. J Urol, 146(1), 66-74 (1991)
102. A. Shukla-Dave, H. Poptani, L. A. Loevner, A. Mancuso, H. Serrai, D. I. Rosenthal, A. M. Kilger, D. S. Nelson, K. L. Zakian, F. Arias-Mendoza, M. Rijpkema, J. A. Koutcher, T. R. Brown, A. Heerschap and J. D. Glickson: Prediction of treatment response of head and neck cancers with P-31 MR spectroscopy from pretreatment relative phosphomonoester levels. Acad Radiol, 9(6), 688-94 (2002) (Pubitemid 34568804)
103. F. Arias-Mendoza, M. R. Smith and T. R. Brown: Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad Radiol, 11(4), 368-76 (2004) (Pubitemid 38405365)
104. A. Viale, F. Reineri, D. Santelia, E. Cerutti, S. Ellena, R. Gobetto and S. Aime: Hyperpolarized agents for advanced MRI investigations. Q J Nucl Med Mol Imaging, 53(6), 604-17 (2009)
105. B. D. Ross, P. Bhattacharya, S. Wagner, T. Tran and N. Sailasuta: Hyperpolarized MR imaging: neurologic applications of hyperpolarized metabolism. AJNR Am J Neuroradiol, 31(1), 24-33 (2010)
106. K. Golman, R. I. Zandt, M. Lerche, R. Pehrson and J. H. Ardenkjaer-Larsen: Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res, 66(22), 10855-60 (2006)
107. M. J. Albers, R. Bok, A. P. Chen, C. H. Cunningham, M. L. Zierhut, V. Y. Zhang, S. J. Kohler, J. Tropp, R. E. Hurd, Y. F. Yen, S. J. Nelson, D. B. Vigneron and J. Kurhanewicz: Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res, 68(20), 8607-15 (2008)
108. P. E. Larson, R. Bok, A. B. Kerr, M. Lustig, S. Hu, A. P. Chen, S. J. Nelson, J. M. Pauly, J. Kurhanewicz and D. B. Vigneron: Investigation of tumor hyperpolarized [1-13C]-pyruvate dynamics using time-resolved multiband RF excitation echo-planar MRSI. Magn Reson Med, 63(3), 582-91 (2010)
109. S. E. Day, M. I. Kettunen, F. A. Gallagher, D. E. Hu, M. Lerche, J. Wolber, K. Golman, J. H. Ardenkjaer-Larsen and K. M. Brindle: Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med, 13(11), 1382-7 (2007) (Pubitemid 350073590)
110. T. H. Witney, M. I. Kettunen, S. E. Day, D. E. Hu, A. A. Neves, F. A. Gallagher, S. M. Fulton and K. M. Brindle: A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia, 11(6), 574-82, 1 p following 582 (2009)
111. A. L. McKnight, J. L. Kugel, P. J. Rossman, A. Manduca, L. C. Hartmann and R. L. Ehman: MR elastography of breast cancer: preliminary results. AJR Am J Roentgenol, 178(6), 1411-7 (2002) (Pubitemid 34547822)
112. M. Bruehlmeier, U. Roelcke, P. A. Schubiger and S. M. Ametamey: Assessment of hypoxia and perfusion in human brain tumors using PET with 18Ffluoromisonidazole and 15O-H2O. J Nucl Med, 45(11), 1851-9 (2004) (Pubitemid 47618442)
113. M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, C. Uprimny, P. Kovacs, E. Von Guggenberg, R. Bale and I. J. Virgolini: 68Ga-DOTATyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med, 48(4), 508-18 (2007) (Pubitemid 47571404)
114. A. J. Beer, M. Niemeyer, J. Carlsen, M. Sarbia, J. Nahrig, P. Watzlowik, H. J. Wester, N. Harbeck and M. Schwaiger: Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18FGalacto-RGD PET. J Nucl Med, 49(2), 255-9 (2008) (Pubitemid 351225664)